| Autor: |
Shenzhen Tempest-Roe, Maria Prendecki, Stephen P. McAdoo, Candice Clarke, Anisha Tanna, Tabitha Turner-Stokes, Esteban S. Masuda, Michelle Willicombe, H. Terence Cook, Candice Roufosse, David Taube, Charles D. Pusey, Frederick W. K. Tam |
| Přispěvatelé: |
Kidney Research UK |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Antibody mediated rejection is a major cause of renal allograft loss. Circulating preformed donor specific antibodies (DSA) can result as a consequence of blood transfusion, pregnancy or prior transplantation. Current treatment strategies are limited due to partial or transient efficacy, adverse side-effects or patient unsuitability. Previous in vivo studies exploring autoimmune diseases have shown that spleen tyrosine kinase (SYK) signalling is involved in the development of pathogenic autoantibody. The role of SYK in allogenic antibody production is unknown, and we investigated this in a rodent model of sensitization, established by the transfusion of F344 whole blood into LEW rats. Two-week treatment of sensitized rats with selective SYK inhibitor fostamatinib strongly blocked circulating DSA production without affecting overall total immunoglobulin levels, and inhibition was sustained up to 5 weeks post-completion of the treatment regimen. Fostamatinib treatment did not affect mature B cell subset or plasma cell levels, which remained similar between non-treated controls, vehicle treated and fostamatinib treated animals. Our data indicate fostamatinib may provide an alternative therapeutic option for patients who are at risk of sensitization following blood transfusion while awaiting renal transplant. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
